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Understanding of the mechanisms of interaction among nucleoside reverse transcriptase inhibitor (NRTI)-selected mutations in the human
immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) coding sequence is essential for the design of newer drugs and for
enhancing our vision of the structure function relationship among amino acids of the polymerase domain of HIV-1. Although several
nucleoside reverse transcriptase inhibitors select RT mutations K65R and L74V, the combination of 65R + 74V is rare in clinics. A novel
NRTI ()-h-D-dioxolane-guanosine (DXG) is known to select in vitro either the 65R or 74V mutant virus (Antimicrob. Agents Chemother.
44 (2000) 1783). These mutations were not selected together during repeated passaging of the HIV-1 in the presence of this drug. To analyze
the impact of these RT mutations on viral replication, a double mutant containing K65R + L74V was created by site-directed mutagenesis in a
pNL4-3 background. Replication kinetic assays revealed that the mutant K65R + L74V is unstable, and 65R!K reversion occurs during
replication of virus in phytohemagglutinin (PHA)-stimulated human peripheral blood mononuclear (PBM) cells in the absence of selection
pressure. Replication kinetic assays in MT-2 cells demonstrated that double mutant 65R + 74V is highly attenuated for replication and the
initiation of reversion is related to the increase in RT activity. Additionally, the suppression of viral replication in the presence of DXG or
under suboptimal human recombinant interleukin-2 leads to minimal or no 65R!K reversion. These observations provide evidence that
65R!K reversion in the double mutant 65R + 74V is dependent on a specific rate of viral replication in a pNL4-3 background. A similar
phenomenon may occur in vivo, which may have implications for treatment management strategies.
D 2004 Elsevier Inc. All rights reserved.Keywords: Human immunodeficiency virus type 1 (HIV-1); Drug resistance; Viral replication; Replication fitness; Reversion; Proviral DNA; Human
interleukin-2 (IL-2)
Introduction with lethal mutations generated during in vitro selection, orTo combat replication-competent, drug-resistant variants,
the continuous development of novel nucleoside reverse
transcriptase inhibitors (NRTI) that are effective against
drug-resistant variants of human immunodeficiency virus
type 1 (HIV-1) is warranted. This requires understanding the
interactions between drug(s) and specific amino acid resi-
dues of the polymerase domain of HIV-1. More essential is
understanding which amino acids are altered during in vitro
selection of drug-resistant isolates. One caveat is that viruses0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: plsharm@emory.edu (P.L. Sharma).in those individuals being treated with specific drug regi-
mens, are not available for further analysis.
The selection of HIV-1 reverse transcriptase (RT) muta-
tions K65R and L74V during passaging with ()-h-D-
dioxolane-guanosine (DXG) has been demonstrated by sev-
eral investigators (Bazmi et al., 2000; Gu et al., 1999;
Mewshaw et al., 2002). One of the interesting findings is
that the passaging of HIV-1 in the presence of DXG (Bazmi
et al., 2000) or ()-h-D-2,6-diaminopurine-dioxolane
(DAPD, Andoxovir) (Mewshaw et al., 2002) results in the
isolation of either K65R or L74V in separate experiments.
The K65R mutation is found infrequently in viral isolates
from patients treated with didanosine (ddI) and deoxycyti-
dine (ddC) (Gu et al., 1994a; Winston et al., 2002; Zhang et
al., 1994). However, its clinical relevance is increasing
because K65R has been identified in a significant number
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(R)-9-(2-phosphonylmethoxypropyl)adenine, DXG, and
abacavir (Bazmi et al., 2000; Foli et al., 1996; Gu et al.,
1995a; Harrigan et al., 2000; Miller et al., 2000; Schinazi et
al., 2000; Selmi et al., 2001; Wainberg et al., 1999).
Similarly, the ddI-selected L74V mutation is now shown to
be selected by several other NRTIs both in vitro and in vivo
(Schinazi et al., 2000).
The occurrence of double mutation L74V with K65R is
extremely rare (Stanford HIV drug resistance database at
web site, http://hivdb.stanford.edu). Monitoring genotypes
of the virus in 23 subjects who had received 1–2 years of
didanosine monotherapy, one patient showed the presence
of these two mutations together (Winters et al., 1997). The
possibility of compensatory mutations playing a role in the
stability of 65R + 74V RT or the amplification of a
replication incompetent virus containing these double muta-
tions could not be ruled out in this single rare case. Apart
from the absence of double mutation 65R + 74V during the
selection of HIVLAI in the presence of lead NRTI candidates
DXG and DAPD, the double mutant has also not been
selected in the presence of other FDA-approved NRTI,
abacavir. Notably, both 65R and 74V RT mutations are
selected in various combinations with other RT mutations
during abacavir monotherapy, but the doubly mutant 65R +
74V is not observed (Harrigan et al., 2000). These obser-
vations were striking and provided us a unique opportunity
to study the interactions between amino acid residues 65 and
74 in the polymerase domain of pNL4-3 virus. We hypoth-
esized that these two mutations are incompatible.
We demonstrate here that the double mutant 65R + 74V in
a pNL4-3 background is unstable, and a rapid 65R!K
reversion occurs during replication of the virus in human
peripheral blood mononuclear (PBM) cells. Further, by
deliberate interference with viral replication, we provide
evidence that the 65R!K reversion is replication dependent.Results
According to Coffin’s (1995) hypothesis, drug-selected
mutations are replication disadvantaged and thus competed
out by wild-type virus in the absence of selection pressure.Table 1
Oligonucleotides used for PCR and sequencing in this study
Primer
designation
Primer sequence Tm
RT 21 5V-CTGACTTGCCCAATTCAATTTCCCCACTAA-3V 63
RT 16 5V-CCAGTAAAATTAAAGCCAGGAATGGATGGCCC-3V 65
74F 5V-GTAGGACCTACACCTGTCAAC-3V 55
PNL-PR1 5V-CATCATTAGTGTGGGCACCCCTCA-3V 65
Nucleotide numbers are obtained from pNL4-3 sequence GenBank Accession NoTherefore, one of the important considerations during stud-
ies of drug-selected mutations is to monitor them frequently
during passaging by sequencing or by other technologies
used for detecting specific mutations. Such considerations
are highly relevant to this study. Because HIV-1, containing
RT mutations 65R + 74V, is rarely seen in the clinic, and
because these two mutations were not selected together
during passaging of HIVLAI in the presence of DXG, we
analyzed the in vitro compatibility of the two mutations.
The viruses containing point mutations as well as those
with both mutations were produced, and the presence of
mutations was confirmed by sequencing RT-PCR products
using primers listed in Table 1. Codons 1–250 of the RT
gene were sequenced for all the viruses. In the case of double
mutant 65R + 74V, both the protease gene and codons 1–250
in RT were sequenced. The sequence profiles of mutant
viruses produced in PBM cells and 293 cells are presented in
Fig. 1. These viruses were used in different replication and
reversion assays described below.
Mutations K65R and L74V are incompatible in a pNL4-3
background
PBM cells were infected with various dilutions (multiplic-
ity of infection, MOI) of stock viruses containing both
mutations. On day 6, culture supernatants and infected
PBM cells were collected for the determination of mutations
in the RT gene. Sequencing of RT-PCR products and
corresponding genomic DNA revealed that there is a rapid
reversion of 65R!K at RT codon 65 (Fig. 2). It was
interesting to notice that most of the infectious virus (RNA)
was wild type (AAA) at codon 65 at all MOIs tested, whereas
mutation L74V was retained in all dilutions. In contrast to
RNA, the majority (approximately 80–90%) of integrated
DNAwas found to be 65R at lower MOI (at dilutions 1:5000,
1:10000, 1:50000), and mixtures of K65–R65 were found at
higher MOIs (Fig. 2 and Table 2). This suggested that during
the first round of the reverse transcription process, most
cDNAs, and later double-stranded DNA, had both 65R and
74V mutations in the viral RT gene before integration in the
host genome. However, during the subsequent reverse tran-
scription, a rapid 65R!K reversion occurred in the infectious
virus (RNA). Because the majority of integrated viruses(jC) Location in
pNL4-3 sequence
Purpose
.4 3357–3326 Reverse primer for RT-PCR
.9 2573–2604 Forward primer for RT-PCR
.8 2615–2633 Forward sequencing primer for monitoring
nucleotide mixtures (AAA–AGA) at RT
codon 65 and (TTA–GTA) at 74
.1 2207–2232 Forward sequencing primer for monitoring
mutagenesis artifacts in protease gene
. M19921 (Adachi et al., 1986).
Fig. 1. Sequence profiles of viral stocks. Wild-type (pNL4-3) and mutant proviral clones were electroporated in PHA-stimulated PBM cells and chemically
transfected in 293 cells. Efficient viral replication was achieved 3 weeks postelectroporation in PBM cells (RT activity z 2  105 cpm/ml) and 5 day
posttransfection in 293 cells (>500 ng antigen p24). Infectious virus was sequenced after RT-PCR. The portions of chromatograms show that mutations were
retained in the stock viruses that were subsequently used for infection.
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the role of reduced viral replication or a threshold level of
virus to host cells may determine 65R!K reversion.
Because the experiments presented above demonstrated
the 65R!K reversion in a 6-day assay, the presence of both
mutations in culture supernatants collected postelectropora-
tion posed a dilemma. Electroporation of proviral clones
bypass the first step of cDNA synthesis from the viral RNAFig. 2. R!KReversion at codon 65 during replication of pNL4-3 virus containing R
74Vmutations were made in triplicates, and 1 ml of 2 dilutions was added to each
stimulated PBM cells. On day 6, the infected cell cultures were centrifuged, and supe
HIV RNA. The cell pellets were used to monitor the RTsequences in proviral DNA.
DNA sequencer. Chromatogram shows almost complete 65R!K reversion in th
reversion in the proviral DNA at higherMOIs, and the presence of predominantly mu
rate of reverse transcription of mutated HIV RNA at lower MOIs, the majority of cand subsequent steps of double-stranded DNA formation
before integration into the host genome. We stipulate that
the absence of 65R!K reversion in posttransfection super-
natants is due to the reduced replication of the virus. We have
repeated transfection experiments several times and observed
the presence of both mutations in viral RNA. All our stock
viruses were produced through electroporation (in PBM
cells) or chemical transfection (in 293 cells). To avoid theTmutations K65R and L74V. Serial dilutions of viral stock containing 65R +
well in a 24-well plate. Each well was then seeded with 1 ml of 6 105 PHA-
rnatants were collected for measuring RTactivity as well as for sequencing of
Equivalent amounts of PCR products were sequenced on ABI 377 automated
e infectious viruses. The genomic DNA sequence profile shows 65R!K
tated codon AGA at lowMOIs. These observations suggested that at reduced
DNA and double-stranded DNA had parental 65R + 74V mutations.
Table 2
Reversion of mutation R!K at RT codon 65 during replication of double
mutant virus 65R + 74V in human PBM cells
RT codon 65
Virus dilutions Genomic DNA
(%WT/mutant)
RNA
(%WT/mutant)
1:10 50/50 100/0
1:50 73/27 100/0
1:100 50/50 100/0
1:500 64/36 100/0
1:1000 NA 100/0
1:5000 32/68 100/0
1:10000 19/81 100/0
1:50000 16/84 100/0
The percentages of WT nucleotide A (in codon AAA) and mutant
nucleotide G (in codon AGA) was calculated by measuring peak heights
(Nurpeisov et al., 2003) at codon 65 in chromatogram (see Fig. 2). NA, not
amplified.
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done.
Once we have determined that a rapid reversion occurs
at RT codon 65 in mutant virus 65R + 74V, it was not
feasible to perform various assays by normalizing virus
concentrations from TCID50s. Thus, the input viruses
were normalized by the antigen p24 or RT activity in
all the assays.Fig. 3. A rapid 65R!K reversion during replication of the virus with 65R + 74V m
of mutant viruses (6  104 cpm RT activity/106 PBM cells) for 2 h. The cells were
infected cells were seeded in a 24-well plate (2 ml/well). Culture supernatants we
were performed and nucleotide peaks were analyzed at codons 65 and 74. Chrom
Mutated codon 74V (GTA) was retained in all the samples. No reversion was o
mutations 65R and 74V in the background of pNL4-3 are incompatible.Kinetics of reversion in double mutant virus
To determine how rapid 65R!K reversion occurs, we
performed a time point experiment, in which culture super-
natants collected on days 1, 3, 4, and 6 postinfection were
analyzed for mutations at RT codons 65 and 74 (Fig. 3).
Visualizing sequences from HIV RNA isolated as early as
day 1 revealed the presence of K/R amino acid mixtures at
codon 65. Comparing the peak heights of mutated nucleo-
tide G versus A revealed the reversion of R!K in 60%
(approximately) of the total population. On days 3, 4, and 6,
only a minor population of AGA codon was present, and the
majority of virus was AAA (WT) codon (z80%). In
comparison to 65R, the second mutation 74V was retained
in all HIV RNA samples collected at various time points. In
contrast, no reversion was observed at any time point with
point mutants 65R or 74V (Fig. 3). These observations
provide evidence that mutations 65R and 74V in a pNL4-3
background are incompatible.
Decreased RT activity of 65R + 74V viruses during
replication in PBM cells
Because viruses containing either K65R or L74V RT
mutations are attenuated for replication (Sharma and Crum-
packer, 1997, 1999;White et al., 2002), we compared relativeutations. PHA-stimulated PBM cells were infected with equivalent amounts
washed with 10 ml of RPMI and resuspended in 16 ml of fresh medium. The
re collected on days 1, 3, 4, and 6 postinfections. RT-PCR and sequencing
atogram shows a rapid 65R!K reversion at codon 65 as early as day 1.
bserved in point mutants 65R or 74V. These results provide evidence that
Fig. 4. Attenuated replication of 65R + 74V viruses in MT-2 cells. To assure
the presence of a homogenous population of input viruses, the viruses
produced in 293 cells were used for infection. The input viruses were
normalized from antigen p24 concentrations. Two million MT-2 cells were
infected with each of the RT variants, 65R, 74V, 65R + 74V, and WT virus,
for 2 h at 37 jC in the presence of 5% CO2. Infections were terminated by
the addition of 10 ml of RPMI. Infected cells were pelleted and resuspended
in 10 ml of RPMI (minus IL-2). Culture supernatants were collected on
different days until day 20, and antigen p24 and RT activity were
determined. Comparing relative antigen p24 production on day 16 for WT,
74V, 65R, and 65R + 74V viruses revealed an 11.8-fold decrease virus
production for double mutant with respect to point mutants 65R and 74V
and a 16.4-fold decrease in comparison to WT virus. A similar pattern of
replication kinetic was observed when the relative RT activities were
plotted. Sequencing of viral RNA obtained on days 1–16 revealed that both
65R and 74 V mutations were retained in double mutant. Because infectious
viral RNA was present in culture supernatants collected as early as day 1,
these results suggest that the double mutant is highly crippled in the
presence of both 65R and 74V mutations. However, the increase in viral
replication on day 20 (B) of double mutant showed a marginal (15% WT)
65R!K reversion.
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and 74V viruses. Because at lowMOI the majority of proviral
DNA molecules had mutant codon AGA (65R) (see Fig. 2),
we rationalized that infecting PBM cells at lower MOI would
result in the absence of reversion. This would allow us to
compare replication kinetics of point mutants and double
mutant viruses. Infections were performed at low MOI (6 
104 cpm RT activity/106 PBM cells). On day 6 postinfection,
relative RT activities for 65R + 74V, 65R, and 74V viruses
were 6.9  104, 9.0  104, and 1.7  105 cpm/ml, respec-
tively. Even under these assay conditions, a partial 65R!K
reversion (30% WT) was observed in 65R + 74V viruses.
These observations suggested that 65R + 74V viruses would
have shown a further decrease in replication capacities or
reduction in RT activity in the absence of reversion.
Highly attenuated replication of 65R + 74V viruses in MT-2
cells
Previous studies have demonstrated that lamivudine-se-
lected M184V viruses replicate inefficiently in PBM cells
but similar to wild-type viruses in T-cell lines, such as Sup
T1 cells (Back et al., 1996). These differences in replication
capacities were attributed to increase dNTP pools in T-cell
lines as compared to PBM cells. Because PBM cell-based
replication assays showed a rapid 65R!K reversion, we
hypothesized that the double mutant viruses (65R + 74V)
would replicate inefficiently in MT-2 cells and may result in
the absence or delayed reversion at codon 65.
To avoid 65R!K reversion in the double mutant, we
generated viruses in 293 cell lines that do not support viral
replication. Infections were normalized by infecting MT-2
cells with viral culture supernatants containing equivalent
amounts of antigen p24. Comparing the production of
antigen p24 or RT activity by WT, 65R, 74V, and 65R +
74V viruses revealed that the double mutant is highly
crippled for replication in MT-2 cells (Fig. 4). On day 16,
the relative antigen p24 production was 145, 105, 104, and
8.8 ng/ml for WT, 74V, 65R, and 65R + 74V viruses,
respectively. This revealed an 11.8-fold decrease virus
production for double mutant with respect to point mutants
65R and 74V and a 16.4-fold decrease in comparison to WT
virus. Similarly, the production of RT activity on day 16 was
2.4  105, 1.8  105, 1.1  105, and 4.2  104 cpm/ml for
WT, 74V, 65R, and 65R + 74V viruses, respectively.
Sequencing of viral RNA obtained on days 1–16 revealed
that both 65R and 74 V mutations were retained in the
double mutant. Because infectious viral RNAwas present in
culture supernatants collected as early as day 1, these results
suggest that double mutant is highly crippled in the presence
of both 65R and 74V mutations. However, the increase in
viral replication or RT activity of double mutant is related to
65R!K reversion.
We further evaluated the effect of decreased viral repli-
cation on 65R!K reversion using the RT inhibitor DXG
and suboptimal IL-2 concentrations (see below).65R!K reversion in the presence of lower DXG
concentrations
We noticed that during certain replication assays, com-
plete 65R!K reversion was not achieved, similar to the one
observed previously (Fig 2). Because RT activities of WT
and mutant viruses in these assays were 3–4-fold lower than
obtained normally, this may be due to the variability in the
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the absence of reversion in MT-2 cells was related to a
decreased level of viral replication. We hypothesized that the
level of 65R!K reversion is based on the replication ca-
pacity (RT activity) of the virus. It has been shown previ-
ously that RT mutations K65R and L74V in the background
of HIV-1LAI confer an 8.7- and 4.2-fold increase in resistance
to DXG, respectively, in comparison to wild-type virus in
MT2 cells (Bazmi et al., 2000). We analyzed whether
deliberate interference with viral replication in the presence
of DXG would result in nonreversion of 65R to 65K in
double mutant viruses. Previous studies have shown an EC50
of 2.41 AM for DXG against HIV-1LAI containing the 65R
mutation (Bazmi et al., 2000). We conducted our experiment
with DXG in the range of 0.1–10 AM.
Analysis of sequence chromatograms at various DXG
concentrations revealed that at lower drug concentrations of
0.1, 0.2, 0.4, and 0.8 AM, AGA–AAAmixtures were present
(Fig. 5). In contrast, at higher DXG concentrations of 1.6,
3.2, and 10 AM, most infectious viruses (>90%) were AGA
(65R). These observations indicated that a specific level of
viral replication (reverse transcription) is required to achieve
a complete (or partial) 65R!K reversion in double mutant
virus. It could be argued, however, that a minor wild-type
(65R/K + 74V) population was present in the initial viral
stock, and that the replication capacity (fitness) of such
viruses is greater than that of the double mutant viruses in
the presence of lower DXG concentrations. Additionally, this
minor viral population (65K + 74V) might have increased
susceptibility at higher drug concentrations in comparison
with the predominant population of double mutant virusesFig. 5. Optimal viral replication is required for 65R!K reversion in double muta
double mutant virus containing RT activity equivalent to 3.3  105 cpm for 2 h.
cells. The infected PBM cells were resuspended in 15 ml of fresh RPMI. One mil
milliliter of various DXG dilutions (2) was added in duplicates onto infected cells
RT activity was determined, and sequencing of the infectious virus was performed
analyzed. There was a direct correlation between the extent of viral replication and
concentration that coincided with the highest RT activity (3.6  105 cpm/ml). At
(40%) was noted. At higher DXG concentrations of 1.6, 3.2, and 10 AM, AGA (>80
reversion is dependent upon the replication levels of double mutant virus.(65R + 74V). This may have resulted in the presence of
predominantly AGA (65R + 74V) codon at higher drug
concentrations. Under identical conditions, no reversion was
observed in viruses with point mutation 65R or 74V (chro-
matogram not shown). This further suggested that the RT
mutations 65R and 74V are incompatible. However, empha-
sis must be given to the fact that the differential selective
pressure of DXG on different mutant viruses may have an
impact on viral replication and reversion. Also, there is a
possibility that the double mutant has the best fitness to
survive the higher DXG concentrations and the preexisting
double mutant is stable under drug pressure. However, de
novo selection of double mutant during serial passaging
poses the real problem.
We postulated that if limiting certain cellular factor(s)
such as recombinant human IL-2 could control viral repli-
cation, the above dichotomy could be addressed.
Effect of suboptimal IL-2 concentrations on viral replication
and 65R!K reversion
T cell activities are regulated by complex factors or
immunomodulators. As an example, interleukins are sub-
stances produced by cells activated during immune
responses, and they act on other lymphocytes for induction,
maintenance, and control of the immune response. IL-2 is
produced by activated T lymphocytes and stimulates prolif-
eration of different types of T cells. For this reason, IL-2 has
been called T cell growth factor. To enhance T cell prolifer-
ation and optimal viral replication, exogenous IL-2 is re-
quired in the culture medium (RPMI). In our laboratory, 26nt 65R + 74V. Nine million PHA-stimulated PBM cells were infected with
Infection was terminated by adding 10 ml of RPMI and pelleting the PBM
liliter of the infected cells was seeded in duplicates in a 24-well plate. One
, and the plate was incubated at 37 jC in the presence of 5% CO2 for 6 days.
. The sequence profile at RT codons 65 and 74 in relation to RT activity was
65R!K reversion. The maximum reversion was seen at the 0.2 AM DXG
drug concentrations of 0.1, 0.4, and 0.8 AM mixture of AGA (60%)–AAA
%) was the predominant codon. These observations suggested that 65R!K
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rationalized that a suboptimal IL-2 concentration in RPMI
medium would lead to a decreased viral replication resulting
in a decreased or absence of 65R!K reversion.
As expected, suboptimal IL-2 concentrations in RPMI
resulted in a decreased viral replication (Fig. 6). Sequencing
of the infectious viral RNA from day 6 postinfection samples
showed that the predominant genotype in suboptimal IL-2
concentrations of 0.8, 1.6, and 3.2 IU/ml was AGA (65R). In
IL-2 concentrations of 6.5 and 13.0 IU/ml, an equivalent
amount of wild-type (AAA) and mutant (AGA) codons were
present. In contrast, increased 65R!K reversion was ob-
served in optimal IL-2 concentrations of 26 IU, and the
predominant genotype was wild type AAA (70%). No
reversion was observed at codon L74V in double mutant
virus. Because we have observed a complete 65R!K
reversion at optimal IL-2 concentration of 26 IU in the
earlier experiments (Fig. 1), the absence of complete rever-
sion in this assay is attributed to the reduced level of viral
replication probably due to the quality of PBM cells that
restricted optimal viral replication. These observations de-
lineated the paradox that reduced replication of 65R + 74V
viruses, either in the presence of DXG or under suboptimal
IL-2 concentrations, leads to a decreased or absence of
65R!K reversion. In contrast, no reversion was observed
in point mutants 65R or 74V during replication in the
presence of any of the IL-2 concentrations (chromatograms
not shown).Fig. 6. Decreased replication at suboptimal IL-2 concentrations leads to reduced 6
were infected with an equivalent amount of three viruses (3.2  105 cpm RT activ
stopped by adding 10 ml of RPMI without any IL-2, and the infected cells were pe
1 ml was added to each of the 12 wells in a 24-well plate. Subsequently, 1 ml of R
Plates were incubated at 37 jC in the presence of 5% CO2. On day 6, culture sup
analysis. Analysis of RT codon 65 in sequence chromatograms revealed the replica
IL-2 concentrations of 0.8, 1.6, and 3.2 IU/ml resulted in the reduced reversion and
presence of higher IL-2 concentration of 6.5 and 13 IU/ml showed equivalent m
optimal IL-2 concentration of 26 IU/ml, the predominant codon was wild-type A
dependent. Analysis of codon 65 in proviral DNA revealed the presence of wild-ty
MOIs resulted in 65R!K reversion in majority of viral RNA molecules during inIn contrast to RNA, the sequencing of the corresponding
proviral DNA showed that majority of parental molecules
with AGA (65R) were reversed to wild-type codon AAA in
all IL-2 concentrations (Fig 6). This confirmed our earlier
observations that under optimal reverse transcription, the
infectious virus reverts back to wild type at codon 65 as
early as day 1 (see Fig. 3).
The above sequence profile on proviral DNA gener-
ated under suboptimal IL-2 concentrations (Fig. 6) is
different from the proviral DNA generated under various
MOIs (Fig. 2). In the later assay, the virus-to-host cell
threshold ratios played a major role in determining the
extent of 65R!K reversion. At lower MOIs, only a few
RT molecules with 65R + 74V mutations were available
for the initial reverse transcription, which may have
resulted in decreasing overall reverse transcription rate,
allowing faithful reverse transcription of the mutated
RNA. Due to these reasons, majority of the integrated
proviral DNA molecules were AGA (65R). In contrast to
this, the infections were performed at a high MOI, and
the infected cells were subjected to growth under subop-
timal IL-2 concentrations. In these assays, virus-to-cell
ratios were constant and majority of viral RNA molecules
were reverted back to wild type (AAA) presumably
during initiation of reverse transcription by double mutant
RT. These analyses provide evidence that 65R!K rever-
sion depends on the rate of the reverse transcription or
the extent of viral replication.5R!K reversion in double mutant. PHA-stimulated PBM cells (8.4  106)
ity) containing mutations 65R, 74V, and 65R + 74V for 2 h. Infections were
lleted. The cells were resuspended in 12 ml of fresh RPMI (minus IL-2), and
PMI containing various 2 concentrations of IL-2 was added to each well.
ernatants were collected for measuring RT activity and HIV RNA sequence
tion-dependent 65R!K reversion. The reduced RT activity with suboptimal
predominant mutated (AGA) codon. A relative increase in RT activity in the
ixtures of AGA–AAA (shown by letter N in chromatogram). However, at
AA (70%). These observations show that 65!K reversion is replication
pe sequence AAA at codon 65. This demonstrated that infections at higher
itial reverse transcription before integration of double-stranded viral DNA.
rology 321 (2004) 222–234 229Reduced replication fitness of the 65R/K + 74V revertant
Although 65R!K reversion occurs rapidly in phytohe-
magglutinin (PHA)-stimulated PBM cells, we hypothesized
that coinfecting the cells with wild-type and 65R + 74V
viruses simultaneously would result in a reduced replication
and absence of 65R!K reversion in the latter. This would
allow us to measure relative replication fitness of mutant
viruses. Nonetheless, evaluating nucleotide peaks in the
chromatogram at codons 65 and 74 showed the complete
dominance of wild-type viruses and the presence of AAA
(>99%) at codon 65 and TTA (approximately 80%) at codon
74, even as early as day 1 (Fig. 7). The sequence analysis of
P.L. Sharma et al. / ViFig. 7. Loss of replication fitness for viruses with 65R + 74V mutations.
PBM cells were coinfected with equivalent amount of wild type pNL4-3
and mutant 65R + 74V viruses. Infections were stopped by the addition of
10 ml of RPMI. Infected cells were pelleted and resuspended in fresh
RPMI. Cultures were incubated at 37 jC in the presence of 5% CO2.
Culture supernatants were collected on days 1, 3, and 6 postinfection. RT-
PCR was performed on viral RNA followed by sequencing of equivalent
amounts (70 ng) of PCR products. Nucleotide peaks at RT codons 65 and
74 were analyzed for reversion. Visualizing 65R + 74V, control virus alone,
a mixture of AGA–AAA (50% each) was observed as early as day 1 at
codon 65. On day 3, AGA was only 20% of a mixture and on day 6,
majority of viruses were wild-type AAA at codon 65. The 74V (GTA) was
retained in all the samples. In contrast to the control, wild-type virus
replication overwhelmed the mutant virus in all the coinfected samples. We
calculated the loss of fitness for transient mutant viruses that are reverting
back to WT genotype during the 6 days of assay. Peak heights of
nucleotides T and G were measured at codon 74, and loss of fitness was
calculated using a mathematical formula (see Materials and methods). The
loss of fitness for 65R + 74V!65R/K + 74V! 65K + 74V was 18% as
compared to wild-type virus.control viruses (65R + 74V) showed the presence of amixture
of AGA–AAA at codon 65, but no change at codon 74. This
explained the differences between the minor population of
viruses AGA (65R) and GTA (74V) on day 1. Similarly, on
day 6, the mixture of TTA–GTAwas observed at codon 74,
and only WT AAA was present at codon 65. In the control,
only a minor population of AGA, 65R (approximately 20%)
was noted on day 3, and on day 6 the predominant viral
species was 65K + 74V. Due to this rapid reversion at codon
65, it was not possible to compare the replication fitness of
65R + 74V viruses with that of the wild type. Sequence
analysis showed that the parental double mutant virus is
continuously reverting back to wild type and thus leading
to mixtures of viruses through day 6 of growth competition
assay.We calculated the putative loss of the replication fitness
for double mutant virus [65R + 74V!65K/R + 74V!65K +
74V] by comparing the peak heights of nucleotides Tand G at
codon 74 on day 6. When compared with the wild-type virus,
the relative loss of replication fitness for doubly mutated virus
was 18% (see Materials and methods).
Previous studies have shown a loss of 11% replication
fitness for L74V viruses (Sharma and Crumpacker, 1997). In
the present study, the mixture of 65R/K + 74V viruses
competed for replication with wild-type virus initially fol-
lowed by the competition between 65K + 74Vand wild-type
viruses. This may have resulted in a more pronounced
increase in the loss of fitness for the double mutant viruses.
In summary, the above-described PBM cell-based assays
as well as MT-2 cell assays provide evidence that 65R + 74V
viruses in a pNL4-3 background produce a significant
decreased level of RT activity and antigen p24 in comparison
to wild-type and the viruses containing point mutations 65R
or 74V. The increase in RT activity was found to be
associated with the initiation of 65R!K reversion. Our
replication assays showed that RT mutations 65R and 74V
are incompatible during optimal viral replication. However,
these two mutations can coexist under suboptimal viral
replication as demonstrated in viral replication assays in
the presence of drug and suboptimal IL-2 concentrations.
Additionally, growth fitness assays demonstrated that double
mutant viruses are extremely impaired (approximately 18%
loss of fitness in a single passage) for replication in compar-
ison to wild-type viruses. Thus, our observations provide a
mechanism for the incompatibility of 65R and 74V muta-
tions and rare occurrence of doubly mutant 65R + 74V
viruses in the clinic.Discussion
This study focused on understanding why RT mutations
65R and 74V were not selected together during passaging of
the virus in the presence of a potent NRTI (DXG). Addi-
tionally, the reason for the paucity of the combination 65R
and 74V in the clinic is obscure (Stanford HIV drug
resistance database at web site, http://hivdb.stanford.edu).
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mutant 65R + 74V and demonstrated that these two muta-
tions are incompatible in a pNL4-3 background, and the
65R!K reversion in the double mutant virus is replication
dependent. Because a rapid reversion (mutant to WT) can be
easily missed during in vitro passaging of viruses or in clinic,
we believe this is the first study to address such concerns.
Our observations provided the mechanism for the absence of
double mutant selection during passaging of HIV1LAI in the
presence of DXG (Bazmi et al., 2000; Gu et al., 1999) and
the rare presence of 65R + 74V viruses during clinical trials
(Winters et al., 1997).
The most common combination of RT mutations selected
in the clinic by abacavir is 74V + 184V; however, other rare
combinations are 65R + 115F + 184Vand 65R + 74V + 115F
+ 184V (Harrigan et al., 2000). Because the combination of
65R + 74V is not observed in the absence of other mutations,
such as M184V and Y115F in clinical trials with abacavir
therapy, the role of 65R!K reversion in the absence of a
double mutant cannot be ruled out. The selection of combi-
nations of triple or quadruple mutants may be due to the
compensatory effect by second site mutation. The appear-
ance of second site mutations are known to restore polymer-
ase function and replication capacity of the HIV-1 that is
debilitated by first RT mutation. For instance, only the
Y115W mutant out of four site directed mutants (Y115L,
Y115A, Y115D, Y115W) was able to replicate in MT-4 cells,
albeit very poorly. Interestingly, sequencing of posttransfec-
tion viruses with increased replications revealed the presence
of M230I second site mutation in addition to primary
mutation Y115W (Olivares et al., 1999).
In the present study, viral replication assays were per-
formed in PBM cells that mimic the in vivo environment
more closely than T cell lines. In MT-2 cells, 65R + 74V
viruses are highly attenuated for replication but retained both
mutations up to day 16 postinfection. This may be due to the
presence of inherent higher dNTP pools in T-cell lines (Back
et al., 1996). The increase in replication rate or RT activity in
MT-2 cells coincided with the 65R!K reversion (Fig. 4).
Thus, a replication-dependent 65R!K reversion in PHA-
stimulated PBM cells and highly attenuated replication in
MT-2 cells may suggest a decrease in the incorporation of
inherent dNTPs during initiation of reverse transcription.
Indeed, recent in vitro studies by other investigators have
shown a decrease in incorporation of all the dNTPs by 65R +
74VRT in comparison to wild-type RTor the RTswith 65R or
74V mutations (Deval J, Navarro J-M, Selmi B, Courcam-
beck J, Boretto J, Halfon P, Sire J, and Canard J. In Antiviral
Therapy, abstract 35, page S41, presented at XII International
HIV Drug Resistance Workshop, 10–14 June, 2003, Los
Cabos, Mexico). Further, no change in the processivity of
double mutant RT was observed during DNA synthesis.
The observations that under suboptimal IL-2 concentra-
tions the 65R!K reversion is decreased are intriguing. After
the initial observations that crude supernatants from PBM
cell cultures induce viral expression in chronically infectedcell lines (Folks et al., 1987), several cytokines that induce
HIV expression have been identified (Poli and Fauci, 1995).
One such cytokine that induces viral expression by upregu-
lating cellular receptors is IL-2 (Fauci, 1996; Loetscher et al.,
1996). Clinical studies have demonstrated that an altered
cytokine and chemokine production characterized by de-
creased IL-2 production can occur in untreated HIV-infected
individuals (Isgro et al., 2002). Taken together, observations
from replication assays performed in the presence of DXG
and IL-2 suggest that a decreased level of viral replication in
the presence of suboptimal levels of cytokines (e.g., IL-2) or
during treatment may modulate the detection of a specific
mutation(s), such as seen in the present study.
Viral dynamic studies have shown that infection with SIV
leads to increased proliferation of T cells in all organs.
Irrespective of the reduced CD4 count in blood, there is a
rapid increase of CD4+ T cells in spleen and lymph nodes. In
contrast, after initial proliferation, the CD4 number is stabi-
lized in nonlymphoid organs (Sopper et al., 2003). These
observations imply that the extent of viral replication will
also vary among organs. This may impact on compartmen-
talization of NRTI and protease inhibitor-selected mutations,
as shown by several investigators (Haddad et al., 2000;
Murry et al., 2003; Poles et al., 2001; Wang et al., 2000).
We speculate that in vivo detection of certain mutation(s),
such as 65R + 74V, may depend upon site-specific HIV
replication.
It has been demonstrated that any change other than Arg
at Lys65 results in an enzyme that exhibits a marked decrease
in the binding affinity [Km] for all dNTP substrates in RT
catalytic efficiency [kcat/Km]. Additionally, the ability of
mutant enzyme to carry out pyrophosphorolysis is compro-
mised (Gu et al., 1994b; Sluis-Cremer et al., 2000). These
studies imply that mutations at position 65 in HIV RT
influence the nucleotide-binding specificity of the enzyme.
According to the above data, the K65R mutation was
expected to attenuate viral replication. In fact, previous
studies have shown that the virus with K65R is identical to
WT in replication efficiency (Gu et al., 1994a). Because RT
with the K65R mutation had shown an increased processiv-
ity in comparison to WT RT, it was assumed that the
increased processivity might be a compensatory mechanism,
allowing the drug-resistant K65R mutant virus to overcome
the inherent disadvantage of decreased affinity for dNTP
substrate, thereby maintaining normal replication capacity
(Arion et al., 1996). In contrast to this, a previous study
demonstrated that K65R and WT RTs possessed similar
processive efficiency, but the K65R RT synthesized full-
length () strong-stop DNA slightly faster than WT RT (Gu
et al., 1995b). In contrast, in a recent study, 65R viruses were
found to have the attenuated replication (White et al., 2002).
We confirmed these observations in the current study. Thus,
the level of viral replication in 65R mutant viruses reported
by different groups is controversial.
Previous studies have demonstrated the role of L74V in
the attenuation of viruses and decreased RT processivity
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that resistance mutations have the tendency to revert back to
WT depending upon the extent of in vitro or in vivo infection
(MOI) or length of passaging viruses in the absence of a
drug. We have previously demonstrated that a 74V!L
reversion can occur during replication of 74V virus at lower
MOIs but this mutation retained at higher MOIs (Sharma and
Crumpacker, 1997). A V!M reversion of lamivudine-se-
lected M184V is attributed to treatment interruption in
clinical trials (Harrigan et al., 2000). More recent studies in
the SIV monkey model have shown that the reversion of
184V virus to 184M was selected by PMPA (tenofovir) even
in the presence of ()-h-2V-3V-dideoxy-5-fluoro-3V-thiacyti-
dine [()-FTC, Emtriva] (Murry et al., 2003). Because
PMPA selects for 65R mutation, further reversion studies
to understand interactions between 65R and 184V mutations
are required.
The major difference between 65R!K reversion demon-
strated in this study and the reversion of point mutants
(discussed above) is that the former is extremely rapid under
optimal conditions, and such reversions are almost impossi-
ble to note during clinical trials. Additionally, the above-
mentioned studies have implications in the interpretation of
the results of in vitro growth competition assays. It is utmost
important to determine if the extent of loss of fitness is due to
a decreased replication rate or decreased infection of PBM
cells by mutant viruses and not due to the reversion of HIV
variant under specific assay conditions.
Amino acids Lys65 and Leu74 are part of the highly
flexible h3–h4 linkage group in the fingers domain of the
66-kDa subunit of HIV-1 RT. The HIV RT crystal structure
shows that the incoming triphosphate moiety is coordinated
by Lys65 and Arg72, main-chain-NH groups of residues 113
and 114, and two Mg2+ ions. Further, Arg72 donates hydro-
gen bonds to the a-phosphate and the q-amino group of
Lys65 donates hydrogen bonds to the g-phosphate. As a
result of finger closure, both of these side chains move into a
specific position. The closing down of the fingertips traps
both the template strand due the interaction of Leu74 with
the templating base and the dNTP (Huang et al., 1998). Thus,
the elucidation of interactions between residues 65 and 74
derived from the structure of a covalently trapped catalytic
complex of HIV RT suggests that the major influence due to
changes K!R and L!Vat residues 65 and 74, respectively,
may occur during initiation or reinitiation and not during
processive synthesis. Our observations suggest that a similar
phenomenon may be occurring in vivo, which may have
implications in HIV-1 infection management.Materials and methods
Cells, media, and virus
Leucopacs were obtained from Advance Biotechnolo-
gies, Inc. (ABI, Columbia, MD) and peripheral bloodmononuclear (PBM) cells were separated by ficoll-hypaque
(Histopaque 1077; Sigma) density gradient centrifugation
and stimulated with phytohemagglutinin (PHA, 2 Ag/ml) in
RPMI 1640, supplemented with 20% heat-inactivated fetal
bovine serum, recombinant human interleukin 2, IL-2 (26
IU/ml), 250 U/ml penicillin, 250 Ag/ml streptomycin, and 2
mM L-glutamine for 48–72 h before virological study
(Sharma and Crumpacker, 1997, 1999). Primary human
embryonic kidney cells 293 (contributed by Andrew Rice)
and the proviral clone pNL4-3 (contributed by M. Martin)
were obtained from the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH.
Preparation of mutant viruses
Site-directed mutagenesis was performed to create pro-
viral clones with point mutations K65R and L74V, and a
double mutant with both K65R + L74V mutations in a
pNL4-3 background, using the pALTER mutagenesis sys-
tem (Promega, WI) (Sharma et al., 1996). Previously
described protocols were used for plasmid transfection and
viral propagation (Sharma and Crumpacker, 1997, 1999).
Briefly, wild-type (WT) clone pNL4-3 and mutants K65R,
L74V, and 65R + 74V were transfected in PHA-stimulated
PBM cells by electroporation, and the replication of the
virus was monitored by measuring the RT activity in cell-
free supernatants. Three weeks posttransfection, culture
supernatants were collected for RNA extraction and to
confirm the presence of mutations in the infectious virus.
Culture supernatants were saved at 70 jC until further use.
To avoid reversion of RT mutants, mutant viruses were
also produced in non-T cell cell line 293 (primary human
embryonic kidney cells). Cells were maintained in DMEM
supplemented with 10% heat-inactivated fetal bovine serum.
Cells were splitted 24–48 h before transfection to obtain
70–80% confluence. Proviral DNA (5–10 Ag) is transfected
with SuperFect transfection reagent (Quiagen, Valencia,
CA) according to manufacturer’s protocol. Culture super-
natants were collected 5 days posttransfection and the levels
of antigen p24 were determined using RETRO-TEK HIV-1
p24 antigen ELISA kit (ZeptoMetrix Corporation, Buffalo,
NY).
Amplification of infectious viral RNA and genomic DNA
Total RNA was isolated from culture supernatants using
the commercial QIAmp Viral RNA mini kit (Quiagen). A
784-bp RT fragment was amplified by single-step RT-PCR
of RNA using primers RT21 and RT16 (Table 1). Both WT
and mutated fragments were purified using QIAquick PCR
purification kit (Quiagen). In case of genomic DNA, infected
cells were washed twice with phosphate-buffered saline and
pelleted. Cells were lysed in buffer containing proteinase K
(500 Ag/ml), sodium dodecyl sulfate (0.5%), Tris–HCl (10
mM), NaCl (30 mM), and EDTA (20 mM) at 37 jC for 3 h.
Genomic DNA was isolated by extracting the cell lysate
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isoamyl alcohol–chloroform followed by precipitation in the
presence of 2.5 M ammonium acetate and isopropanol. One
microgram of genomic DNA was amplified using primers
RT21 and RT16 (Table 1). The PCR products were purified
as discussed above.
DNA was quantified by measuring optical density at
wavelengths of 260–280 nm in a Beckman spectrophotom-
eter. To avoid variability among independent sequencing
reactions due to repeated freeze and thaw, aliquots of
purified DNA were stored at 20 jC. Each aliquot of
DNA was used only once during the sequencing reaction.
Determination of tissue culture infectious dose (TCID50)
Cell-free viruses were diluted in RPMI medium from
1:10 to 1:100000 in triplicates in 24-well plates, and 6 
105 PHA-stimulated PBM cells were added to each well.
Culture supernatants were collected on day 6 for measuring
RT activity and RNA isolation. The last dilution with a 10-
fold higher RT activity over background was considered one
TCID50. TCID50s were determined for wild-type pNL4-3
virus and other RT mutants.
Determination of 65R!K reversion in double mutant
65R + 74V
To determine if mutations are retained during replication
of viruses containing 65R + 74V mutations, infections were
performed at several multiplicity of infection (MOI) from
stock viruses as discussed above. On day 6, cell-free culture
supernatants were collected for determining the RT activity
and for isolation of HIV RNA, and the infected cells were
collected for genomic DNA extraction. RT-PCR was per-
formed to determine the genotype in the infectious RNA, and
genomic DNA sequencing was performed to analyze paren-
tal mutations in integrated viruses.
Similar experiments were also conducted in a time point
assay. PHA-stimulated PBM cells were infected with
equivalent amount of viruses for 2 h at 37 jC in the
presence of 5% CO2. Infections were terminated by the
addition of 10 ml of RPMI medium. The infected cells
were centrifuged briefly, resuspended in fresh RPMI, and
seeded in a 24-well plate. Culture supernatants were collect-
ed on days 1, 3, 4, and 6 postinfection. The reversion of
double mutant viruses was monitored at both the 65 and 74
RT codons by sequencing and analyzing nucleotide peaks in
chromatogram.
Determination of replication kinetics and reversion of RT
variants in MT-2 cells
The viruses generated in non-T cell line 293 were used in
this assay to assure the presence of specific RT mutations.
Two million MT-2 cells were infected with equivalent
amounts (8 ng antigen p24) of each of the RT variants65R, 74V, 65R + 74V, and wild-type virus for 2 h at 37
jC in the presence of 5% CO2. The infections were termi-
nated by adding 10 ml of RPMI followed by centrifugation at
400  g for 10 min at 4 jC. The infected cell pellets were
suspended in 5 ml of RPMI and cultures were incubated at 37
jC in the presence of 5% CO2. To monitor viral replication
and the presence of RT mutations, culture supernatants were
collected on several days until day 20. The cultures were
replaced with the fresh RPMI. The HIV-1 antigen p24 and
virion-associated reverse transcriptase activity were deter-
mined to monitor viral replication. The infectious viral RNA
was amplified by RT-PCR and sequencing was performed to
determine the fate of respective mutations.
Monitoring mutations 65R and 74V during replication of
double mutant virus in the presence of DXG
Either K65!R or L74!V is selected during passaging
of HIVLAI viruses in DXG (Bazmi et al., 2000). We wanted
to determine if these mutations are retained during con-
trolled replication of double mutant virus in the presence of
DXG. Ten million PBM cells were infected with each of the
RT variants, 65R, 74V, 65R + 74V, and WT virus, for 2 h.
Infected cells were washed with 10 ml of RPMI medium
and the cell pellet was suspended in 16 ml of fresh RPMI.
One milliliter of infected cells was added to 16 wells in a
24-well plate followed by addition of 1 ml of seven-drug
concentration (2) ranging from 0.1 to 10 AM in duplicates.
One milliliter of drug-free medium was added in control
wells. On day 6, culture supernatants were collected to
measure the RT activity and to confirm the presence of
parental mutations in infectious virus. RT-PCR and sequenc-
ing were performed as discussed above.
Determination of the stability of double mutant virus under
suboptimal IL-2 concentrations
We routinely use 26 IU/ml of human recombinant IL-2
during preparation of complete RPMI medium. We wished
to determine if the rate of viral replication or the rate of
reverse transcription affects the stability of RT mutations
65R and 74V during replication of double mutant virus
under suboptimal IL-2 concentrations. Twofold dilutions of
recombinant IL-2 were made in IL-2-free RPMI medium to
achieve final concentrations between 0.8 and 26 IU/ml.
Eight million PHA-stimulated PBM cells were infected for
2 h with each of the RT variants (65R, 74V, 65R + 74V)
containing 3  105 cpm/ml of the RT activity. Infected cells
were washed with 10 ml of IL-2-free RPMI, and the pellet
was suspended in 12 ml of IL-2-free medium. One milliliter
of infected cells was added to each of the 12 wells (24-well
plate) containing RPMI medium with various IL-2 concen-
trations. The plates were incubated at 37 jC in the presence
of 5% CO2. On day 6, culture supernatants were collected
for determining RT activity and the fate of mutations 65R
and 74V.
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Growth competition assays were performed by coinfect-
ing PBM cells with an equivalent amount (RT activity = 3 
104 cpm/106 PBM cells) of wild-type and double mutant 65R
+ 74V viruses, and then comparing the fitness of one virus in
relation to the other over a period of time. Similar to other
assays, infections were done for 2 h at 37 jC followed by
termination of infection by the addition of 10 ml of RPMI.
Subsequently, cells were pelleted, resuspended in fresh
RPMI, and incubated at 37 jC in the presence of 5% CO2.
Infectious viruses were collected on days 1, 3, and 6 and RT-
PCR and sequencing were performed. The replication fitness
was determined by monitoring the extent of virus replication
as depicted by the presence of the mixture of nucleotides
(codons) at a single locus.
In comparing replication fitness between WT and double
mutant 65R + 74V viruses, both RT codons 65 and 74 were
monitored for the presence of the mixture of mutant (G) and
wild-type (A) nucleotides at codon 65 and mutant (G) and
wild-type (T) at codon 74, respectively. The less fit virus will
show a decrease in peak height over a period of time. To
calculate the loss in fitness, the percentage of relative peak
heights for both nucleotides at various time points was
determined and the selection coefficient (s = fitness differ-
ence) was determined by the following mathematical model:
s = 1/t 1n[ q(t)p(0) / p(t)q(0)]; where t = total time of passage;
q(t) = more fit population; p(t) = less fit population; p(0) =
q(0) = 0.5 (Goudsmit et al., 1996; Nagylaki, 1992; Sharma
and Crumpacker, 1997).
Determination of reversion
The reversion of mutant viruses during replication in
PBM cells was monitored by sequencing. We have recently
validated the fluorescent dye-terminator sequencing (ABI
377) approach for the quantification of viruses in a mixture
(Nurpeisov et al., 2003). To establish a correlation between
the peak heights and the amount of DNA for each variable,
we sequenced the mixtures of known amount of the wild-
type and mutant DNA. This approach allowed us to detect
15–20% of the minor DNA population in a mixture. In case
of reversion, the peak heights at RT codons 65 and 74 were
measured and the percentages of wild-type and mutated
nucleotides were calculated.Acknowledgments
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